Top Page
Bioxyne Limited
(Sydney:BXN)
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Bioxyne Limited Business Overview & Revenue Model
Bioxyne Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.17M | 30.42M | 9.33M | 5.16M | 463.64K | 2.11M |
| Gross Profit | 16.41M | 10.45M | 3.40M | 343.13K | -224.10K | 639.71K |
| EBITDA | 9.59M | 5.34M | -13.03M | -1.88M | -463.30K | -425.93K |
| Net Income | 8.97M | 4.90M | -13.33M | -1.94M | -494.02K | -495.73K |
Balance Sheet | ||||||
| Total Assets | 34.63M | 20.90M | 6.70M | 17.69M | 445.59K | 2.68M |
| Cash, Cash Equivalents and Short-Term Investments | 7.60M | 7.67M | 1.03M | 3.85M | 65.93K | 1.60M |
| Total Debt | 7.43M | 1.53M | 710.42K | 558.61K | 397.39K | 47.46K |
| Total Liabilities | 14.45M | 9.53M | 3.40M | 2.69M | 810.43K | 744.75K |
| Stockholders Equity | 20.17M | 11.68M | 3.61M | 15.14M | -364.84K | 1.88M |
Cash Flow | ||||||
| Free Cash Flow | -62.22K | 3.86M | -4.05M | -897.92K | -566.88K | 19.47K |
| Operating Cash Flow | 2.02M | 6.28M | -3.56M | -841.28K | -506.81K | 53.13K |
| Investing Cash Flow | -1.74M | -2.41M | -492.66K | 4.10M | 26.61K | -33.66K |
| Financing Cash Flow | 4.66M | 2.76M | 1.21M | 805.36K | 493.24K | -46.78K |
Bioxyne Limited Technical Analysis
Bioxyne Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$132.15M | 3.18 | 61.21% | ― | 204.87% | ― | |
74 Outperform | AU$125.25M | 4.99 | 10.07% | 2.19% | 38.25% | 361.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$35.84M | 22.20 | -31.14% | ― | -15.07% | 29.45% | |
42 Neutral | AU$7.00M | -0.92 | -184.71% | ― | 39.53% | 49.99% | |
41 Neutral | AU$5.70M | -1.62 | -60.84% | ― | -18.70% | 20.83% | |
41 Neutral | AU$25.75M | -33.08 | ― | ― | 6.76% | ― |
Bioxyne Limited Corporate Events
Bioxyne has upgraded its FY26 adjusted EBITDA guidance to a range of $16.5 million to $19.0 million, up from $11.5 million to $13.5 million, after a stronger than expected first half. The company delivered H1 FY26 adjusted EBITDA of $8.3 million, more than double the prior corresponding period, while revenue rose to $31.3 million and full-year revenue guidance remains unchanged at $65 million to $75 million.
Management attributes the earnings uplift to successful margin expansion initiatives and efficient scaling of the business rather than any change in topline expectations. The improved profitability signals stronger operational leverage in Bioxyne’s expanding pharmaceuticals and controlled substances portfolio, reinforcing its positioning in alternative therapeutics and supporting expectations for a robust full-year result for investors and other stakeholders.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited reported a sharp improvement in its financial performance for the half year to 31 December 2025, with revenue from continuing operations rising 149% to $31.3 million and net profit attributable to members more than doubling to $7.3 million. Net tangible assets per security also increased 165% to 0.9 cent, while the company again opted not to declare a dividend, indicating a focus on reinvestment and balance sheet strengthening.
The group confirmed there were no changes in control of entities, no associates or joint ventures, and that its accounts were free of audit disputes, underscoring operational stability as it scales. With Breathe Life Sciences expanding Bioxyne’s footprint in controlled substances and alternative therapeutics across multiple regions, the robust half-year results highlight growing commercial traction in its pharmaceuticals and medicinal cannabis businesses.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited, through subsidiary Breathe Life Sciences, has begun commercial supply of GMP-manufactured psilocybin capsules to authorised prescribers in Queensland and Western Australia for use in treatment-resistant depression and other mental health research. The company’s BLSPSIL25 capsules meet Australian and international pharmaceutical standards, positioning Bioxyne as an early mover in Australia’s tightly regulated psychedelic-assisted therapy market.
Initial orders cover 250 doses to treat around 60 patients over the next year, a small slice of an estimated 300,000 Australians living with treatment-resistant depression, but management says manufacturing can scale significantly to meet growing demand. With mental illness affecting a large portion of the population and global psychedelic drug markets forecast to expand rapidly, the move validates Bioxyne’s strategic investment in psychedelic therapeutics and could open a pathway to larger commercial opportunities if clinical and regulatory momentum continues.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has applied for quotation on the ASX of 14,480,556 new fully paid ordinary shares, to be listed under its ticker BXN. The shares have been issued under an employee incentive scheme and are scheduled to be quoted from 30 January 2026, modestly increasing the company’s quoted capital base and reflecting ongoing use of equity-based remuneration for staff and executives.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has appointed Pitcher Partners in Brisbane as its new external auditor following a tender process, aligning its audit function more closely with the location of its Australian operations. As an independent member of global network Baker Tilley International, Pitcher Partners is expected to support Bioxyne’s expansion in the UK and Germany, while the company’s board has acknowledged and thanked outgoing auditor RSM Australia Partners for its long-standing service.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has released a presentation of its second-quarter FY2026 results, emphasising that the material is a high-level, summary document that may change without notice and should not be treated as complete or definitive. The company stresses that numerous statements in the presentation are subject to risks and uncertainties, disclaims liability for reliance on the information, and clarifies that the document is neither an offer of securities nor financial product advice, urging investors to seek independent professional guidance before making any investment decisions.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has informed the ASX that it is cancelling a previously lodged notice relating to the cessation of certain securities. The company clarified that an earlier Appendix 3H filed on 19 December 2024, which recorded the lapsing of 10,333,334 performance rights, had already been included in a subsequent Appendix 3H lodged on 22 March 2024, prompting the formal cancellation of the redundant December filing as of 16 January 2026.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has reported a change in the interests of director Samuel Watson, reflecting additional equity-based incentives tied to performance outcomes and shareholder approvals. Watson’s direct holding in Bioxyne increased by 20 million ordinary shares, awarded as a result of achieving 2025 performance milestones, and his performance rights rose to 39 million following resolutions approved at the company’s annual general meeting on 26 November 2025. These changes, implemented at no cash consideration, further align the director’s interests with those of shareholders and underscore the company’s ongoing use of equity incentives to retain and motivate key leadership.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has issued 85.5 million unquoted performance rights under its employee incentive scheme, effective 24 December 2025. The substantial grant of performance rights, which will not be quoted on the ASX, signals an increased emphasis on equity-based remuneration to align employees’ and executives’ interests with shareholders, potentially leading to future dilution but aimed at supporting staff retention and performance as the company pursues its strategic objectives.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has applied to the ASX for quotation of 30 million new fully paid ordinary shares, issued on 23 December 2025. The shares have been issued under an employee incentive scheme, signalling the company’s use of equity-based remuneration to align staff interests with shareholders and potentially broaden its free float, subject to market reception once the securities commence trading.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has announced the issuance of unquoted equity securities, specifically 2,200,000 options expiring on March 26, 2027 with an exercise price of $0.05. This development reflects the company’s actions in managing its unquoted equity securities potentially as part of ongoing transactions or strategic financial initiatives.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited announced a change in the director’s interest, with Mr. Anthony Ho participating in a capital raise approved by shareholders. This move, involving the acquisition and gifting of securities, reflects strategic adjustments in the company’s financial operations, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has issued a total of 5,600,000 shares, with 4,400,000 shares allocated to directors as part of a capital raise and 1,200,000 shares to consultants in lieu of cash payments. This move, approved by shareholders, reflects the company’s strategic financial management and compliance with relevant sections of the Corporations Act, indicating a stable regulatory standing.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has announced the issuance of 1,200,000 ordinary fully paid securities as part of an agreement to issue shares in lieu of cash payment for an invoice. This move is part of the company’s strategic financial management, potentially impacting its liquidity and shareholder value by conserving cash while fulfilling financial obligations.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has secured a manufacturing and supply agreement with Remidose LATAM SRL, marking its entry into the emerging medicinal cannabis markets of Costa Rica and Panama. This strategic move positions Bioxyne as a first-mover in these high-potential, low-competition markets, with the agreement potentially generating over A$1 million in annual revenue. The partnership underscores Bioxyne’s expertise in producing pharmaceutical-grade, non-flower formats like pastilles and aligns with their growth trajectory targeting significant revenue and EBITDA in FY26.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
Bioxyne Limited has appointed Mr. Paul Mitchell as the Chief Financial Officer of its subsidiary, Breathe Life Sciences, to enhance its financial leadership amid rapid growth. Mr. Mitchell’s extensive experience in strategic planning and pharmaceutical manufacturing will support the company’s expansion in manufacturing and distributing controlled medicines, including medicinal cannabis, psilocybin, and MDMA, across Australia and the UK, aligning with Bioxyne’s ambitious international strategy.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.